51165-02-7

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(1-ethynylcyclohexyl)piperidine is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique structural properties and reactivity contribute to the development of novel drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(1-ethynylcyclohexyl)piperidine serves as a versatile building block for creating a wide range of chemical compounds. Its ethynyl and cyclohexyl groups provide opportunities for further functionalization and the formation of complex molecular structures.
Used in Medicinal Chemistry:
1-(1-ethynylcyclohexyl)piperidine is utilized as a structural motif in medicinal chemistry, where it can be incorporated into drug molecules to enhance their pharmacological properties. Its presence in a molecule may improve binding affinity, selectivity, or other desirable characteristics, leading to more effective therapeutic agents.

Upstream product

• 110-89-4 piperidine 
• 6209-75-2 1-ethynyl-1-chlorocyclohexane 
• 78-27-3 1-Ethynylcyclohexan-1-ol 
• 5240-32-4 1-acetoxy-1-ethynyl cyclohexane 
• 108-94-1 cyclohexanone 
• 142-45-0 Acetylenedicarboxylic acid 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 109440-25-7 1-(1-ethynyl-cyclohexyl)-1-methyl-piperidinium; iodide 
• 144776-81-8 2-cyclohexylidene-3-(dimethylphenylsilyl)propanal 
• 880255-24-3 1,3-dimethyl-7-(phenylethynyl)-6-((1-(piperidin-1-yl)cyclohexyl)ethynyl)pteridine-2,4(1H,3H)-dione 

Relevant academic research and scientific papers

α-Tertiary Propargylamine Synthesis via KA2-Type Coupling Reactions under Solvent-Free CuI-Zeolite Catalysis

The potential of copper(I)-zeolite catalysis was evaluated in the three-component KA2-coupling mediated synthesis of α-tertiary propargylamines. Our archetypal copper(I)-doped zeolite CuI-USY proved to be efficient under ligand- A nd solvent-free conditions at 80 °C. Usable up to four times, this catalytic material enables the coupling of diverse ketones, alkynes, and amines with a broad functional group tolerance. A decarboxylative and a desilylative version, respectively, involving an alkynoic acid and trimethylsilylacetylene as alkyne surrogates, was also set up to bypass selectivity issues and/or to access α-tertiary propargylamines that are unattainable under standard KA2 conditions. Interestingly, the KA2-type coupling reactions were successfully linked to other CuI-catalyzed reactions, thus resulting in sequential one-pot processes under full CuI-USY catalysis.

N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT

The present invention provides an excellent squalene synthase inhibitor. Specifically, it provides a compound (I) represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 represents an optionally substituted vinyl group or an aromatic ring which may be substituted; ???n is an integer of 0 to 2; ???X, Y and Z are the same as or different from each other and each represents an optionally substituted carbon atom, or an optionally substituted nitrogen a tom, sulfuratomoroxygenatom, and Y optionally represents a single bond, and when Y represents the single bond, the ring to which X, Y and Z belong is a 5-membered ring; ???CyA represents a 5- to 14 membered non-aromatic cyclic amino groupornon-aromatic cyclic amidogroupwhichmaybe substituted, and the non-aromatic cyclic amino group or the non-aromatic cyclic amido group optionally having an oxygen atom or a sulfur atom; ???W represents a chain expressed by(1) optionally substituted -CH2-CH2-,(2) optionally substituted -CH=CH-,(3) -C≡C-,(4) an optionally substituted phenylene group,(5) a single bond,(6) -NH-CO-,(7) -CO-NH-,(8) -NH-CH2-,(9) -CH2-NH-,(10) -CH2-CO-,(11) -CO-CH2-,(12) -O-(CH2)m-,(13) -(CH2)m-O- (where m represents an integer of 0 to 5),(14) -O-CH2-CR2=,(15) -O-CH2-CHR2- (where R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom),(16) -NH-S(O)1-,(17) -S(O)1-NH-,(18) CH2-S(O)1-, or(19) -S(O)2-CH2- (where 1 represents 0, 1, or 2); and ???A represents a group having any of the following structural formulae: (wherein R3 and R4 represent independently a hydrogen atom or an optionally substituted C1-6 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; ???R5 and R6 represent independently a hydrogen atom or an optionally substituted C1-6 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; ???R7 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; ???R8 represents a hydrogen atom, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; ???B1 represents an optionally substituted carbon atom, or an optionallysubstitutednitrogenatom, oxygen atom or sulfur atom; ???B2 represents an optionally substituted carbon atom or nitrogen atom; ???a and b represent an integer of 0 to 4, provided that a+b is an integer of 0 to 4; ???c represents 0 or 1; and----- represents a single bond or a double bond, provided that when c is 1 in which A is a quinuclidine having R8 represented by the case where R8 is a hydrogen atom or a hydroxyl group; Arl is an aromatic heterocycle; and W is one of (1) to (3), (6) to (11) and (16) to (19) are excluded).